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Abstract A thorough evaluation of headache in children
and adolescents is necessary to make the correct diagnosis
and initiate treatment. In part 1 of this article (O ¨zge et al. in J
Headache Pain, 2010), we reviewed the diagnosis of head-
ache in children and adolescents. In the present part, we will
discuss therapeutic management of primary headaches. An
appropriate management requires an individually tailored
strategy giving due consideration to both non-pharmacolog-
ical and pharmacological measures. Non-pharmacological
treatments include relaxation training, biofeedback training,
cognitive-behavioural therapy, different psychotherapeutic
approaches or combinations of these treatments. The data
supporting the effectiveness of these therapies are less clear-
cut in children than in adults, but that is also true for the data
supporting medical treatment. Management of migraine and
TTH should include strategies relating to daily living activ-
ities, family relationships, school, friends and leisure time
activities.Inthepharmacologicaltreatmentageandgenderof
children, headache diagnosis, comorbidities and side effects
of medication must be considered. The goal of symptomatic
treatment should be a quick response with return to normal
activity and without relapse. The drug should be taken as
early as possible and in the appropriate dosage. Supplemen-
tary measures such as rest in a quiet, darkened room is rec-
ommended. Pharmaco-prophylaxis is only indicated if
lifestyle modiﬁcation and non-pharmacological prophylaxis
alone are not effective. Although many prophylactic medi-
cationshavebeentriedinpaediatricmigraine,thereareonlya
few medications that have been studied in controlled trials.
Multidisciplinary treatment is an effective strategy for chil-
dren and adolescents with improvement of multiple outcome
variants including frequency and severity of headache and
school days missed because of headache. As a growing
problembothchildrenandfamiliesshouldbeinformedabout
medication overuse and the children’s drug-taking should be
checked.
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Introduction
Headache is the most common complaint in children and
adolescents. The incidence of childhood migraine and
frequent headache has substantially increased over the past
30 years. The increased incidence is alarming and may be
secondary to lifestyle changes but also due to increased
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ache (especially migraine and tension type headache, TTH)
is the most important cause of headaches in this age group.
In part 1 of this article [1] we reviewed the diagnosis of
headache in children and adolescents. In the present part,
we will discuss therapeutic management.
Management of headaches
The general principles of management of headache in
children and adolescents can be summarized as follows:
• Establish the diagnosis.
• Look for possible somatic and psychiatric comorbidi-
ties [2–6].
• Ask for triggers and assess degree of disability.
• Educate the child and family about the condition.
• Use a headache calendar to establish the characteristics
of headache and associated symptoms.
• Establish realistic expectations and set appropriate
goals.
• Discuss the expected beneﬁts of pharmacological and
non-pharmacological therapy and the time course to
achieve them.
• Reduce the emotional mechanisms (on a personal level,
within the family and at school) that provoke stress and
may favour headache attacks.
• Advise to maintain a sound rhythm in daily life, which
includes regular meals, sufﬁcient ﬂuid intake, physical
exercise and sleep.
• Advise how to cope with trigger factors.
An algorithm for the diagnostic and therapeutic man-
agement of migraine is shown in Fig. 1.
Non-pharmacological treatments
Non-pharmacological treatment of migraine
Behavioural interventions, particularly biofeedback and
relaxation therapy have demonstrated their effectiveness in
the treatment of both adults and older children with
migraine in controlled trials. The physiological basis for
their effectiveness is unclear, but data from one trial sug-
gest that levels of plasma beta-endorphin can be altered by
relaxation and biofeedback therapies. The data supporting
the effectiveness of behavioural therapies are less clear-cut
in children than in adults, but that is also true for the data
supporting medical treatment. This is due in part to
methodological issues, especially the lack of speciﬁc tests
for migraine, which has hampered research and helped
leading to an inappropriate de-emphasis on care for
childhood headache. In addition, migraine headaches in
children are often briefer and have a higher rate of spon-
taneous remission than those experienced by adults, mak-
ing it difﬁcult to separate effective from ineffective
treatments [7–9].
Starting from the consideration that children and ado-
lescents with headache show greater indices of psychopa-
thology [10–14] and show higher risk of developing
psychological disorders in adulthood than healthy controls
[15], different psychotherapeutic approaches are some-
times provided in clinical practice. Relaxation and cogni-
tive-behavioural techniques have been found to reduce the
intensity and frequency of headache in children and ado-
lescents [16, 17].
Prospective, randomized, partly double-blind, placebo-
controlled, parallel-group trial showed that Butterbur root
extract and music therapy might be superior to placebo and
may represent promising treatment approaches in the pro-
phylaxis of paediatric migraine [18].
The specialists involved in the assessment and care of
headache patients should strive to increase their knowledge
of alternative therapies, so as to be better equipped to guide
patients towards safe, economical and potentially effective
treatments, rather than useless, costly or dangerous ones.
Non-pharmacological treatment of TTH
Behavioural headache treatments include relaxation train-
ing, biofeedback training, cognitive-behavioural therapy or
combinations of these treatments. Among behavioural
headache treatments, the two most common types of bio-
feedback for headache have been electromyographic bio-
feedback for TTH and ‘‘handwarming’’ or thermal
biofeedback for migraine [9, 19–22]. Magnesium salt
seems to be effective in treating the paediatric episodic and
chronic TTH (ETTH, CTTH), but further well-controlled
studies are needed [23].
There are restricted data about the natural history of
childhood and adolescent TTH. It is accepted that over than
50% of the sufferers improve with a comprehensive
headache managements. The most important predictors of
prognosis are comorbid medical and psychological condi-
tions and family problems [24, 25].
Pharmacological treatments
Pharmacological treatment of migraine
The data on efﬁcacy and safety of medications in children
are limited. Therefore, it may be necessary to use medi-
cations off label strictly weighing up the beneﬁts and risks.
However, medications which have shown efﬁcacy in adults
must not be used routinely in younger patients (please refer
to Ref. [26]). Only few randomized placebo-controlled
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123clinical trials have been conducted in paediatric headache
patients for both acute and preventive drugs. Moreover, the
few published studies show a high placebo response rate in
children, up to 55% for prophylactic drugs, up to 69% for
symptomatic ones. Such high placebo response rates
drastically reduce the possibility to ﬁnd effective agents
(in terms of statistically signiﬁcant superiority over pla-
cebo) and may lower the interest of pharmaceutical com-
panies and independent researchers to perform new clinical
trials in this ﬁeld. On the other hand, the placebo effect is a
psychobiological phenomenon that can be attributed to
different mechanisms [27]; it should be properly used by
Fig. 1 Algorithm for the
diagnostic and therapeutic
management of migraine
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123the physician, simply bearing in mind that any medical
treatment is surrounded by a psychosocial context that
affects the therapeutic outcome.
The pharmacological treatment of migraine consists of
symptomatic and/or prophylactic therapy. The former is
aimed at relieving or ameliorating the symptoms of an acute
attack, whereas prophylactic therapy, which requires the
daily intake of medication for a certain period of time,
decreasesthefrequencyoftheattacksandtheseverityofpain.
Symptomatic drug treatment Thegoal oftreatment should
be a quick response with return to normal activity and
withoutrelapse.Severalkeyconceptsshouldbemadeknown
to patients. Medication use should be limited to avoid med-
ication overuse headache. It is important that an appropriate
dose isused. Medicationsshouldbe taken shortly after onset
of migraine headache to optimize the effect, even though
scientiﬁc evidence supporting this recommendation is lack-
ing.Themedicationshouldbeavailabletothepatientsalsoat
school.Allodyniaduringamigraineinadultscorrelateswith
responsetotreatmentof acutemigraine with triptansand the
progressive nature of migraine. This has emphasized the
importanceofearlyrecognitionofheadacheandappropriate
treatment. Allodynia has recently been shown to be present
in 37% of children during their migraine. Allodynia is often
not routinely evaluated during a headache history even
though there may be potential therapeutic implications.
Prominent scalp symptoms include sensitivity to touch and
difﬁculty brushing hair [28–30].
The available efﬁcacy data about symptomatic drugs
[31–46] are summarized in Tables 1 and 2. The following
ﬁndings should be kept in mind:
• At 1 h acetaminophen tended to be slightly more
effective (39% of children relieved) than ibuprofen
(37% of children relieved), but 2 h after administration
ibuprofen was more effective (68 vs. 54%).
• Sumatriptan nasal spray was superior to placebo and
was well tolerated. No serious adverse events occurred
with taste disturbance as the most common one.
• Pain relief at 2 h was achieved in signiﬁcantly more
attacks treated with rizatriptan 5-mg tablets (77%) or
with rizatriptan 5-mg wafer (77%) than with standard
care (64%).
• Pain relief rates after 2 h were 28% for placebo, 62% for
zolmitriptan and 69% for ibuprofen (placebo vs. zolmi-
triptan p\0.05; placebo vs. ibuprofen p\0.05). Both
drugs are well tolerated with only mild side effects.
• The Food Drug Administration has recently approved
almotriptan for the acute treatment of migraine head-
ache in adolescents. Nevertheless, almotriptan is still
not approved in Europe.
• There are limited data about other triptans.
• In summary, there is moderate evidence that analgesics
(acetaminophen and ibuprofen) and nasal-spray suma-
triptan are more effective than placebo treatment.
Based on the available literature, no differences in
effect were found between the different compounds.
There is a lack of studies addressing the question of
treatment in the emergency department of children with
migraine. Future studies should focus on ﬁnding the best
ﬁrst-line agent for mild to moderate attacks in the emer-
gency department and to conﬁrm the usefulness of pro-
chlorperazine as treatment for severe attack or status
migrainosus. In the latter studies, attention should be given
to adverse drug reactions associated with prochlorperazine.
Furthermore, treatment to decrease the recurrence of
migraine attack and the need for rescue medications after
discharge from the emergency department should also be
carefully evaluated [30, 48].
Prophylactic drug treatment Pharmaco-prophylaxis is
only indicated if lifestyle modiﬁcation and non-pharmaco-
logical prophylaxis alone are not effective. Although many
prophylactic medications have been tried in paediatric
migraine, there are only a few medications that have been
studied in controlled trials. Prophylactic medications are
recommended only when migraines are occurring with suf-
ﬁcient frequency (usually 3–4 per month) and severity to
impact a patient’s daily function or quality of life (e.g.
missing school). To minimize adverse effects, prophylactic
medicationsarestartedatthelowestdoseandtitratedupward
as needed. They have to give a through time period (at least
4–6 months), and both comorbidities and side effects of the
drug have to be taken into consideration [30, 49].
Prophylactic drugs evaluated in placebo-controlled and
open-label trials for migraine [50–71] have been summa-
rized in Table 3. The following ﬁndings should be kept in
mind:
• Flunarizine is an effective drug. Its use is limited by
daytime sedation found in 10% of the patients and
weight gain in more than 20%. Because of probable D2
receptor interaction it should not be given for more than
3 months (administering it in the early evening can
avert daytime sleepiness, dosage 5 mg/die) [72, 73].
• Propranolol was found to be superior to placebo in one
randomized controlled trial and not effective in two
others. It was found to activate asthma in subjects with
atopic disorders or a positive history of atopic disorders,
and there are no follow-up studies concerning long-term
risks of betablockers. Therefore, some centres do not
use betablockers for migraine prophylaxis in children.
• The overall positive response rate of cyproheptadine
was 83% and common side effects included sedation
and increased appetite.
28 J Headache Pain (2011) 12:25–34
123Table 1 Symptomatic drugs for migraine management evaluated in placebo-controlled and open clinical trials
References Drug Study
design
Evidence
level
Dose Age
(years)
Number of
patients
Responders (%) p value
Active
drug
Placebo
Hamalainen et al. [31] Ibuprofen RCT A 10 mg/kg 4–16 88 68 37 \0.05
Lewis et al. [32] Ibuprofen RCT 7.5 mg/kg 6–12 84 76 53 0.006
Evers et al. [33] Ibuprofen RCT 200–400 mg 6–18 32 69 28 \0.05
Hamalainen [31] Acetaminophen RCT B 15 mg/kg 4–16 88 54 37 \0.05
Hamalainen et al. [34] Dihydroergotamine RCT C 20, 40 lg/kg 5–15 12 58 16 NS
Ueberall [35] Sumatriptan nasal RCT A 20 mg 6–10 14 86 43 0.03
Winner et al. [36] Sumatriptan nasal RCT 5–10–20 mg 12–17 510 66
a 53 \0.05
Ahonen et al. [37] Sumatriptan nasal RCT 10–20 mg 8–17 83 64 39 0.003
Winner et al. [38] Sumatriptan nasal RCT 20 mg 12–17 738 61 52 NS
Hamalainen et al. [39] Sumatriptan oral RCT C 50–100 mg 8–16 23 30 22 NS
Mac Donald [40] Sumatriptan sc. OT C 3–6 mg 6–16 17 64 – –
Linder [41] Sumatriptan sc. OT 0.06 mg/kg 6–18 50 78 – –
Winner et al. [42] Rizatriptan RCT C 5 mg 12–17 196 66 56 NS
Visser et al. [43] Rizatriptan RCT 5 mg 12–17 234 68 69 NS
Visser et al. [43] Rizatriptan OT 5 mg 12–17 686 77 – –
Linder and Dowson [44] Zolmitriptan oral OT C 2.5–5 mg 12–17 38 88–70 – –
Evers et al. [33] Zolmitriptan oral RCT 2.5 mg 6–18 32 62 28 \0.05
Charles [45] Almotriptan oral OT B 6.25–12.5 mg 11–17 15 86 – –
Linder et al. [46] Almotriptan oral RCT 6.25–12.5–25 mg 12–17 866 67–73 55 \0.001
Evidence level: ﬁndings regarding symptomatic drugs were reviewed and the recommendations were categorized into different levels (A–C)
[47]. Level A: two or more clinically controlled, randomized studies carried out according to good clinical practice (GCP), versus placebo or
versus active treatment of proven efﬁcacy. Level B: one clinically controlled, randomized study carried out according to GCP or more than one
well-designed clinical case–control study or cohort study. Level C: favourable judgment of two-third of the Ad Hoc Committee members,
historical controls, non-randomized studies, case reports
NS no statistically signiﬁcant difference between active drug and placebo, RCT randomized controlled trial, OT open trial
a 5m g
Table 2 Summary of the efﬁcacy of medication used to treat acute migraine attacks in children and adolescents [45]
Outcome
Pain relief Pain-free Recurrence Need for rescue medications
Oral medication
Acetaminophen (n = 1) ?- - -
DHE (n = 1) -- - -
Ibuprofen (n = 3) ?± - ±
Rizatriptan (n = 3) ±- - ±
Sumatriptan (n = 1) -± - -
Zolmitriptan (n = 2) ±± - ?
Intranasal medication
Sumatriptan (n = 4) ±± - ±
Intravenous medications
Prochlorperazine (n = 1) ? ? - ?
Ketorolac (n = 1)* ? ? ? ? ±
? studies showing consistent positive results or a study showing positive result; - studies showing consistent negative results or a study showing
negative result; ± studies showing inconsistent results; ? not evaluated
* Used as a comparative agent against prochlorperazine
J Headache Pain (2011) 12:25–34 29
123• There are limited conﬁrmative data about trazodone.
• Amitriptyline (1 mg/kg) is an effective drug with an
84.2–89% positive response rate and only mild sedation
was reported as side effect.
• Divalproex sodium (15–45 mg/kg/day) is an effective
drug with 50% headache reduction seen in 78.5% of
patients, 75% reduction in 14.2% of patients, and 9.5%
of patients became headache-free after 4 months of
treatment. The observed side effects were dizziness,
drowsiness and increase in appetite.
• Topiramate is an effective drug for the reduction of
headache frequency, severity and duration. The most
common side effects reported were cognitive (12.5%),
weight loss (5.6%) and sensory (2.8%).
• There are limited data about levetiracetam, gabapentin
and zonisamide.
Table 3 Prophylactic drugs for migraine management evaluated in placebo-controlled and open clinical trials
References Drug Daily dose Age in
(years)
Number of
patients
Study
design
Evidence
level
% responders
or p values (*)
Antihypertensive drugs
Ludvigsson [50] Propranolol 60–120 mg 7–16 28 RCT C 82 vs. 14%
Forsythe et al. [51] Propranolol 80 mg 9–15 39 RCT NS
Olness et al. [52] Propranolol 3 mg/kg 6–12 28 RCT NS
Sillampa ¨a ¨ [53] Clonidine 25–50 lg B15 57 RCT C NS
Sills et al. [54] Clonidine 0.07–0.1 mg 7–14 43 RCT NS
Calcium channel blockers
Guidetti et al. [55] Flunarizine 5 mg 10–13 12 OT A 66%
Sorge et al. [56] Flunarizine 5 mg 5–11 63 RCT p\0.001 (HA frequency)
p\0.01 (HA duration)
Visudtibhan et al. [57] Flunarizine 5–10 mg 7–15 21 OT %66
Battistella et al. [58] Nimodipine 10–20 mg 7–18 37 RCT C NS
Serotonergic drugs
Gillies et al. [59] Pizotifen 1–1.5 mg 7–14 47 RCT C NS
Lewis et al. [60] Cyproheptadine 2–8 mg 3–12 30 OT C 83%
Antidepressants
Battistella et al. [61] Trazodone 1 mg/kg 7–18 35 RCT C NS
Hershey et al. [62] Amitriptyline 1 mg/kg 9–15 192 OT C 80%
Lewis et al. [60] Amitriptyline 10 mg 3–12 73 OT 89%
Anticonvulsants
Caruso et al. [63] Divalproex sodium 15–45 mg/kg 7–16 42 OT B 76%
Sedaroglu et al. [64] Divalproex sodium 500–1,000 mg 9–17 10 OT p = 0.000 (HA severity)
p = 0.002 (HA frequency)
p = 0.001 (HAduration)
Hershey et al. [65] Topiramate 1.4 ± 0.7 mg/kg 8–15 75 OT A p\0.001 (HA frequency)
Winner et al. [66] Topiramate 2–3 mg/kg 6–15 162 RCT NS
Lewis et al. [67] Topiramate 100 mg 12–17 103 RCT 72%
Miller [68] Levetiracetam 250–1,500 mg 3–17 19 OT B p\0.0001 (HA frequency)
Pekalnis et al. [69] Levetiracetam 250–1,500 mg 6–17 20 OT p\0.0001 (HA frequency)
Belman et al. [70] Gabapentin 15 mg/kg 6–17 18 OT C 80%
Pakalnis and Kring [71] Zonisamide 5.8 mg/kg 10–17 12 OT C 66%
Evidence level: ﬁndings regarding symptomatic drugs were reviewed and the recommendations were categorized into different levels (A–C)
[47]. Level A: two or more clinically controlled, randomized studies carried out according to good clinical practice (GCP), versus placebo or
versus active treatment of proven efﬁcacy. Level B: one clinically controlled, randomized study carried out according to GCP or more than one
well-designed clinical case–control study or cohort study. Level C: favourable judgment of two-thirds of the Ad Hoc Committee members,
historical controls, non-randomized studies, case reports
NS no statistically signiﬁcant difference between active drug and placebo, HA headache, RCT randomized controlled trial, OT open trial
* The % is expressed as overall % of responders (OT) or active-drug vs placebo % of responders (RCT); p values refer to active drug versus
placebo comparisons (RCT) or pre-treatment versus post-treatment comparison of headache characteristics (OT)
30 J Headache Pain (2011) 12:25–34
123Pharmacological treatment of TTH
Most TTH is best managed by primary care. ETTH is self-
limiting, but children and their parents generally consult
doctors when headaches occur frequently and are no longer
responsive to analgesics. Medication overuse can be a
common problem in patients with frequent headache. The
treatment of migraine and TTH overlaps. Both require
acute treatment, either behavioural or pharmaceutical.
Behavioural treatment is needed for all types of TTH.
Preventive pharmaceutical treatment is needed for frequent
TTH if lifestyle modiﬁcation and non-pharmacological
treatment alone are not effective. Although childhood TTH
is often treated with medication, few studies have been
published the efﬁcacy of medication in paediatric TTH.
More studies in children need to be done regarding the
treatment of this common disorder. The lack of availability
and cost of non-pharmacological interventions might
diminish the use of some treatment modalities [74, 75].
For acute treatment of ETTH, paracetamol, aspirin and
combination analgesics are effective and inexpensive
drugs. Non-steroidal anti-inﬂammatory drugs are also
effective ﬁrst-line therapeutics for ETTH in adults. In
children younger than 15 years, aspirin is not recom-
mended because of the concern regarding Reye’s syn-
drome. Paracetamol seems to be safe even in young
children [75–78].
Frequent headaches in children and adolescents often
require preventive management. Prophylactic pharmaco-
logical treatment should be considered in CTTH if non-
pharmacological management is inadequate. For children
with frequent headache, amitriptyline might be beneﬁcial,
although no placebo-controlled studies have been per-
formed [62].
Treatment of cluster headache
Several treatment alternatives have been tried in cases
reported in the literature. According to these data, the most
effective symptomatic treatments are oxygen [79–82],
sumatriptan [81, 83] and acetylsalicylic acid [80–84].
Prophylactic treatments reported in literature are predni-
sone/prednisolone [85, 86], indomethacin [84], pizotifen
[81], verapamil [81, 82, 87], methysergide [79, 83, 85],
loratadine [88], astemizole [88] and ﬂunarizine [89]. No
controlled study has been reported.
If oxygen is administered at the onset of an attack via a
non-rebreathing facial mask at a ﬂow rate of at least
7 l/min, approximately 70% of patients will obtain pain
relief within 15 min. This therapy has obvious practical
limitations and requires oxygen being readily available at
the patient’s home [85, 90]. Considering the unbearable
pain intensity, off-label use of sumatriptan nasal spray or
subcutaneous sumatriptan may be necessary. Ergotamine
has also been used. It is not recommended for acute
CH-treatment in children, but might be given in the
evening for preventing night-time attacks. Children
between 6 and 9 years of age should receive 0.1 mg/dose,
those between 9 and 12 years of age should receive
0.5 mg, and those between 12 and 16 years of age should
receive 0.75 mg/dose. Lidocaine applied with a spray
bottle or by dropping in the nostril ipsilateral to pain
achieves moderate pain relief, and it may be useful as an
adjunctive therapy. Although the reason for steroid efﬁcacy
is unknown, the use of cortisone in the acute period can
stop the attacks and may help to prevent further attacks. In
adolescents a marked relief of cluster headache in 77% of
77 episodic cluster headache patients, and a partial relief in
another 12% of patients treated with prednisone was
reported [85, 90]. For prophylactic treatment the efﬁcacy of
verapamil has been attributed to a possible stabilization of
vascular tone. It is generally well tolerated and can be used
in combination with corticosteroids, sumatriptan and
ergotamine [91, 92].
Life quality of headaches
Health-related quality of life (QOL) is an emerging area of
headache research with a direct impact on patient adher-
ence, patient satisfaction and treatment effectiveness. On
the other hand, the assessment of QOL in children is dif-
ﬁcult, since measures must consider children’s changing
cognitive and social development [93, 94]. Data-based
analyses revealed that children with frequent or severe
headaches (FSH) were signiﬁcantly more likely than those
without FSH to exhibit high levels of emotional, conduct,
inattention-hyperactivity, and peer problems and were
signiﬁcantly more likely than children without FSH to be
upset or distressed by their difﬁculties and to have their
difﬁculties interfere with home life, friendships, classroom
learning and leisure activities [95]. Subjects familiar with
headache experienced more stress, fatigue, depression, and
somatic symptoms; they felt less strong, had a less cheerful
mood and reported lower satisfaction with health and with
life in general than the subjects who never had headaches
[96]. The impact of headaches on QOL is similar to that
found for other chronic illness conditions, with impair-
ments in school and emotional functioning being the most
prominent [97]. Headache is the third most common cause
among illness-related causes of school absenteeism
resulting in substantial impairment among paediatric
patients [98]. A speciﬁc questionnaire (PedMIDAS) pro-
vides a tool to assess the impact of migraines in children
and to monitor response to treatment. Further research
should focus on additional validation of the PedMIDAS
J Headache Pain (2011) 12:25–34 31
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lations (e.g. primary care and community samples) [99].
Conclusions
• Management of migraine and TTH should include
strategies relating to daily living activities, family
relationships, school, friends and leisure time activities.
• Management should be completed by education (both
of the children and parents), non-pharmacological
interventions and psychosocial support.
• With reference to symptomatic treatment, the drug
should be taken as early as possible and in the
appropriate dosage. In cases with early onset of nausea
and/or vomiting endorectal or parenteral administration
should be preferred. Antiemetic drugs should not be
provided if the child vomits only once or headache
stops after vomiting. If an antiemetic is required,
ondansetron may be preferred for its good tolerability.
Supplementary measures such as rest in a quiet,
darkened room is recommended.
• Multidisciplinary treatment is an effective strategy for
children and adolescents with improvement of multiple
outcome variants including frequency and severity of
headache and school days missed because of headache.
• In the pharmacological treatment age and gender of
children, headache diagnosis, comorbidities, need and
side effects of medication must be considered.
• As a growing problem both children and families
should be informed about medication overuse and the
children’s drug-taking should be checked.
• Regular follow-up care is needed, especially for those
children with more severe initial headache presentation.
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